uniQure (QURE) Stock Forecast & Price Target

Compare

1,412 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

QURE Analyst Ratings

Strong Buy

10 Buy

2 Hold

0 Sell

Based on 12 analysts giving stock ratings to

uniQure

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

QURE Stock 12 Month Forecast

Average Price Target

$57.40

▲(180.96% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for uniQure in the last 3 months. The average price target is $57.40 with a high forecast of $95.00 and a low forecast of $33.00. The average price target represents a 180.96% change from the last price of $20.43.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","51":"$51","96":"$96","28.5":"$28.5","73.5":"$73.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$57.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$33.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,28.5,51,73.5,96],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.57,31.833846153846153,37.09769230769231,42.361538461538466,47.62538461538462,52.88923076923077,58.153076923076924,63.416923076923084,68.68076923076924,73.94461538461539,79.20846153846153,84.47230769230771,89.73615384615385,{"y":95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.57,28.94153846153846,31.313076923076924,33.684615384615384,36.05615384615385,38.42769230769231,40.79923076923077,43.17076923076923,45.54230769230769,47.91384615384615,50.285384615384615,52.65692307692308,55.028461538461535,{"y":57.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.57,27.064615384615387,27.55923076923077,28.053846153846155,28.548461538461538,29.043076923076924,29.537692307692307,30.032307692307693,30.526923076923076,31.021538461538462,31.516153846153845,32.01076923076923,32.505384615384614,{"y":33,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.66,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.74,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.48,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.99,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.7,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.01,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.99,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.69,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.57,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$95.00

Average Price Target$57.40

Lowest Price Target$33.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Paul Matteis

Stifel Nicolaus

$50→$40

Buy

95.79%

Upside

Reiterated

12/11/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Uy Ear

Mizuho Securities

$60→$33

Buy

61.53%

Upside

Reiterated

12/09/25

Analysts' Top Healthcare Picks: Wave Life Sciences (WVE), uniQure (QURE)We update our model and lower our PT from $60 to $33, due largely to lowering our probability of success and pushing out our launch year for AMT-130 by one year. However, we remain at Outperform as we believe...

Sami Corwin

William Blair

―

Hold

―

Reiterated

12/04/25

Analysts Offer Insights on Healthcare Companies: Immunome (NASDAQ: IMNM), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and uniQure (NASDAQ: QURE)

Patrick Trucchio

H.C. Wainwright

$70

Buy

242.63%

Upside

Reiterated

11/12/25

Positive Long-Term Outlook for uniQure Amid Strong Data and Strategic AdvancementsValuation and Risks. We assess uniQure using a risk-adjusted discounted cash flow (DCF) and sum-of-the-parts (SOTP)- based methodology based on free cash flow to the firm (FCFF) and net income per asset, respectively. We assign a probability of success to with anticipated approval in 2028E. We model a build in revenues tied to uniQure's AAV gene therapy platform in the 2030s, leading to a moderate present value. We employ a 12% discount rate and a terminal multiple of 6.0x. Taken together, these assumptions yield a total firm value of approximately $4.4 billion and price target of $70.

Yanan Zhu

Wells Fargo

$80→$60

Buy

193.69%

Upside

Reiterated

11/12/25

uniQure (QURE) Gets a Buy from Wells Fargo

Joseph Schwartz

Leerink Partners

$68→$60

Buy

193.69%

Upside

Reiterated

11/10/25

uniQure's AMT-130: A Promising Breakthrough in Huntington's Disease Treatment Amidst Regulatory Challenges

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

11/10/25

uniQure's AMT-130: Promising Results Amid Regulatory Challenges Support Buy Rating

Luca Issi

RBC Capital

$45

Buy

120.26%

Upside

Reiterated

11/10/25

RBC Capital Remains a Buy on uniQure (QURE)

Salveen Richter

Goldman Sachs

$56→$38

Hold

86.00%

Upside

Reiterated

11/04/25

uniQure price target lowered to $38 from $56 at Goldman SachsuniQure price target lowered to $38 from $56 at Goldman Sachs

Daniil Gataulin

Chardan Capital

$76→$53

Buy

159.42%

Upside

Reiterated

11/03/25

uniQure price target lowered to $53 from $76 at ChardanuniQure price target lowered to $53 from $76 at Chardan

Kristen Kluska

Cantor Fitzgerald

$47→$80

Buy

291.58%

Upside

Reiterated

09/25/25

uniQure price target raised to $80 from $47 at Cantor FitzgeralduniQure price target raised to $80 from $47 at Cantor Fitzgerald

Debjit Chattopadhyay

Guggenheim

$28→$95

Buy

365.00%

Upside

Reiterated

09/24/25

uniQure price target raised to $95 from $28 at GuggenheimuniQure price target raised to $95 from $28 at Guggenheim

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Paul Matteis

Stifel Nicolaus

$50→$40

Buy

95.79%

Upside

Reiterated

12/11/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Uy Ear

Mizuho Securities

$60→$33

Buy

61.53%

Upside

Reiterated

12/09/25

Sami Corwin

William Blair

―

Hold

―

Reiterated

12/04/25

Analysts Offer Insights on Healthcare Companies: Immunome (NASDAQ: IMNM), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and uniQure (NASDAQ: QURE)

Patrick Trucchio

H.C. Wainwright

$70

Buy

242.63%

Upside

Reiterated

11/12/25

Yanan Zhu

Wells Fargo

$80→$60

Buy

193.69%

Upside

Reiterated

11/12/25

uniQure (QURE) Gets a Buy from Wells Fargo

Joseph Schwartz

Leerink Partners

$68→$60

Buy

193.69%

Upside

Reiterated

11/10/25

uniQure's AMT-130: A Promising Breakthrough in Huntington's Disease Treatment Amidst Regulatory Challenges

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

11/10/25

uniQure's AMT-130: Promising Results Amid Regulatory Challenges Support Buy Rating

Luca Issi

RBC Capital

$45

Buy

120.26%

Upside

Reiterated

11/10/25

RBC Capital Remains a Buy on uniQure (QURE)

Salveen Richter

Goldman Sachs

$56→$38

Hold

86.00%

Upside

Reiterated

11/04/25

uniQure price target lowered to $38 from $56 at Goldman SachsuniQure price target lowered to $38 from $56 at Goldman Sachs

Daniil Gataulin

Chardan Capital

$76→$53

Buy

159.42%

Upside

Reiterated

11/03/25

uniQure price target lowered to $53 from $76 at ChardanuniQure price target lowered to $53 from $76 at Chardan

Kristen Kluska

Cantor Fitzgerald

$47→$80

Buy

291.58%

Upside

Reiterated

09/25/25

uniQure price target raised to $80 from $47 at Cantor FitzgeralduniQure price target raised to $80 from $47 at Cantor Fitzgerald

Debjit Chattopadhyay

Guggenheim

$28→$95

Buy

365.00%

Upside

Reiterated

09/24/25

uniQure price target raised to $95 from $28 at GuggenheimuniQure price target raised to $95 from $28 at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering uniQure

1 Month

xxx

Success Rate

10/18 ratings generated profit

Average Return

+11.23%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +11.23% per trade.

3 Months

xxx

Success Rate

10/18 ratings generated profit

Average Return

+30.86%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +30.86% per trade.

1 Year

Patrick TrucchioH.C. Wainwright

Success Rate

16/22 ratings generated profit

Average Return

+53.30%

reiterated a buy rating last month

Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +53.30% per trade.

2 Years

xxx

Success Rate

19/22 ratings generated profit

Average Return

+137.33%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 86.36% of your transactions generating a profit, with an average return of +137.33% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

QURE Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, QURE has received 14 Buy Ratings, 12 Hold Ratings, and 1 Sell Ratings. QURE average Analyst price target in the past 3 months is 57.40.

Each month's total comprises the sum of three months' worth of ratings.

QURE Financial Forecast

QURE Earnings Forecast

Next quarter’s earnings estimate for QURE is -$0.92 with a range of -$1.06 to -$0.69. The previous quarter’s EPS was -$1.38. QURE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year QURE has Performed in-line its overall industry.

QURE Sales Forecast

Next quarter’s sales forecast for QURE is $5.29M with a range of $3.50M to $10.30M. The previous quarter’s sales results were $3.70M. QURE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year QURE has Performed in-line its overall industry.

QURE Stock Forecast FAQ

What is QURE’s average 12-month price target, according to analysts?

Based on analyst ratings, uniQure N.V.’s 12-month average price target is 57.40.

What is QURE’s upside potential, based on the analysts’ average price target?

uniQure N.V. has 180.96% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is QURE a Buy, Sell or Hold?

uniQure N.V. has a consensus rating of Strong Buy which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.

What is uniQure N.V.’s price target?

The average price target for uniQure N.V. is 57.40. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $95.00 ,the lowest forecast is $33.00. The average price target represents 180.96% Increase from the current price of $20.43.

What do analysts say about uniQure N.V.?

uniQure N.V.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of QURE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

uniQure (QURE) Stock Forecast & Price Target

QURE Analyst Ratings

QURE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering uniQure

QURE Analyst Recommendation Trends

QURE Financial Forecast

QURE Earnings Forecast

QURE Sales Forecast

QURE Stock Forecast FAQ

Detailed List of Analyst Forecasts